ETOILE: Real-World Evidence of 24 Months of Ranibizumab 0.5 mg in Patients with Visual Impairment Due to Diabetic Macular Edema.
Laurent KodjikianAmélie Lecleire-ColletCorinne DotMarie-Laure Le LezStéphanie BaillifAli ErginayEric SouiedEric FourmauxPhilippe GainAnne PonthieuxPublished in: Clinical ophthalmology (Auckland, N.Z.) (2021)
Real-world ranibizumab treatment improved VA in DME patients, despite fewer injections than recommended.